[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-443911-105":59,"doc-detail-443911-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","trends-of-advanced-chronic-liver-disease-among-17711-persons-in-mongolia-during-years-2015-2023","Trends of Advanced Chronic Liver Disease Among 17,711 Persons in Mongolia During Years 2015-2023","","Chronic liver diseases impose a substantial health burden in Asia. This cross-sectional study characterizes advanced chronic liver disease (aCLD) patterns and associated factors in a large Mongolia cohort, using HBsAg-tested adults (≥18 years) with liver stiffness measurement and/or platelet count from a hepatology center (2015–2023). aCLD was defined as LSM ≥12.5 kPa or platelets \u003C150×10^9/L. Among 17,711 attendees, 14.2% had aCLD, with notable HBsAg and viral co-infection prevalence, a decline in overall aCLD linked to falling anti-HCV cases, and increasing chronic hepatitis D cases; most patients had intermediate-to-high HCC risk, indicating urgent care and therapy access needs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/trends-of-advanced-chronic-liver-disease-among-17711-persons-in-mongolia-during-years-2015-2023/443911/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/trends-of-advanced-chronic-liver-disease-among-17711-persons-in-mongolia-during-years-2015-2023/443911.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-02","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was advanced chronic liver disease (aCLD) defined in the study?","Question",{"text":112,"@type":113},"aCLD was defined as liver stiffness measurement (LSM) ≥12.5 kPa or platelet count \u003C150×10^9 cells/L.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did the study find about trends in aCLD from 2015 to 2023?",{"text":117,"@type":113},"The overall aCLD rate declined (APC −7.8%), mainly driven by declining anti-HCV+ cases (APC −15.0%), while anti-HDV+ cases increased (APC 3.3%) over the study period.",{"name":119,"@type":110,"acceptedAnswer":120},"What proportion of participants with aCLD were at intermediate to high risk of hepatocellular carcinoma (HCC)?",{"text":121,"@type":113},"Among those with aCLD, three-fourths had intermediate to high 5-year HCC risk, with 25.0% at that level.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},443911,1790869603,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Journal of  \nViral Hepatitis  \n|  ORIGINAL ARTICLE  OPEN ACCESS \u003Cbr>Trends of Advanced Chronic Liver Disease Among 17,711 Persons in Mongolia During Years 2015–2023\u003Cbr>Habiba Kamal1,2  | Ganbolor Jargalsaikhan3,4 | Sanjaasuren Enkhtaivan3,4 | Daniel Bruce5 | Karin Lindahl1,2 | Bekhbold Dashtseren3,4  | Tuvshinjargal Ulziibadrakh3,4 | Munguntsetseg Batkhuu3,4 | Purevjargal Bat-Ulzii3,4 | Sumiya Byambabaatar3,4 | Soo Aleman1,2  | Naranjargal B. Dashdorj3,4\u003Cbr>1Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden | 2The Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden | 3The Liver Centre, Ulaanbaatar, Mongolia | 4ONOM Foundation, Ulaanbaatar, Mongolia | 5Cytel Statistical Consultancy, Stockholm, Sweden\u003Cbr>Correspondence: Habiba Kamal ([habiba.khodir.kamal@ki.se](habiba.khodir.kamal@ki.se))\u003Cbr>Received: 24 June 2025 | Revised: 24 September 2025 | Accepted: 2 December 2025\u003Cbr>Keywords: cirrhosis | HBV | HCV | HDV | mongolia |  |\n| --- | --- |\n| ABSTRACT\u003Cbr>Chronic liver diseases cause a significant burden in Asia. This study aims to characterise the pattern and factors associated with advanced chronic liver disease (aCLD) in a large cohort from Mongolia, which has the highest rate of liver cancer globally. This is a cross-sectional analysis of HBsAg tested adults (≥18years) with available liver stiffness measurement (LSM) and/or platelet count at initial visit at a hepatology centre, Ulaanbaatar, Mongolia during 2015–2023. Definition of aCLD was LSM ≥12.5 kPa or platelet count \u003C 150*109 cells/L. The annual percentage change (APC) of the incidence rates and factors associated with aCLD were assessed via logistic regression models. Out of 17,711 persons identified, 2517 (14.2%) had aCLD at initial visit, with a mean age (±SD) of 50.1 (12.0) years, 23.6% below 40 years old and 53.2% were female. The prevalence of HBsAg+, anti-HDV+, HDV RNA+, and anti-HCV+ was 61.6%, 78.6%, 64.6% and 57.9% in aCLD, respectively. Among aCLD, three-fourths had an intermediate to high 5-year risk of hepatocellular carcinoma (HCC) with 25.0%, and 17.1% having previously received anti-HBV and anti-HCV therapies, respectively. The overall rate of aCLD declined (APC −7.8%), mainly due to decline in anti-HCV+ cases (APC −15.0%), while it significantly increased for anti-HDV+ over study period (APC 3.3%) . In a large cohort of attendees at a hepatology centre in Mongolia, the prevalence of aCLD declined associated with decreasing HCV infection, while chronic hepatitis D constituted the majority of increasing cases. A minority received therapy, with most patients showing an intermediate to high risk of liver cancer. More efforts are needed to improve linkage to care and access to therapy, especially in middle-aged individuals at higher risk of liver disease progression. |  |\n| 1 | Introduction | to advanced chronic liver disease (aCLD) and hepatocellular |\n| Chronic liver disease causes a significant health burden in Asia [1] . In 2019, nearly 50% and 75% of global deaths related | carcinoma (HCC), respectively, occurred in the Asia-pacific region [1] . Nonetheless, aCLD, including cirrhosis is a cause of disability-adjusted life-years, highly impacting people aged |\n| Abbreviations: aCLD, advanced chronic liver disease; APC, annual percentage change; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HDV, hepatitis D virus; LSM, liver stiffness measurement; MASLD, metabolic dysfunction-associated steatotic liver disease; MRF, metabolic risk factor; PAGE-B score, platelets age gender risk score.\u003Cbr>Soo Aleman and Naranjargal B. Dashdorj shared last authorship. |  |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2026 The Author(s). Journal of Viral Hepatitis published by John Wiley & Sons Ltd. |  |\n\nJournal of Viral Hepat","cbCaimZuSblDoZkT","https://ap.wps.com/l/cbCaimZuSblDoZkT","pdf",849514,"English","# Introduction\n# Materials and Methods\n## Study Design, Population and Setting","[{\"question\":\"How was advanced chronic liver disease (aCLD) defined in the study?\",\"answer\":\"aCLD was defined as liver stiffness measurement (LSM) ≥12.5 kPa or platelet count \\u003c150×10^9 cells/L.\"},{\"question\":\"What did the study find about trends in aCLD from 2015 to 2023?\",\"answer\":\"The overall aCLD rate declined (APC −7.8%), mainly driven by declining anti-HCV+ cases (APC −15.0%), while anti-HDV+ cases increased (APC 3.3%) over the study period.\"},{\"question\":\"What proportion of participants with aCLD were at intermediate to high risk of hepatocellular carcinoma (HCC)?\",\"answer\":\"Among those with aCLD, three-fourths had intermediate to high 5-year HCC risk, with 25.0% at that level.\"}]","Trends of Advanced Chronic Liver Disease Among 17,711 Persons in Mongolia During Years 2015-2023 | PDF",1790706032,23]